[1] GBD MORTALITY AND CAUSES OF DEATH COLLABORATORS. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013:a systematic analysis for the Global Burden of Disease Study 2013[J]. Lancet,2015,385(9963):117-171. [2] GOLDSTEIN S T,ZHOU F J,HADLER S C,et al. A mathematical model to estimate global hepatitis B disease burden and vaccination impact[J]. Int J Epidemiol,2005,34(6):1329-1339. [3] 郑文灿,余梅,法艳梅. 恩替卡韦在慢性乙型肝炎治疗中的应用进展[J]. 临床合理用药杂志,2018,11(13):177-179. [4] MAINI M K,GEHRING A J. The role of innate immunity in the immunopathology and treatment of HBV infection[J]. J Hepatol,2016,64(1 Suppl):S60-S70. [5] GEHRING A J,PROTZER U. Targeting innate and adaptive immune responses to cure chronic HBV infection[J]. Gastroenterology,2019,156(2):325-337. [6] 刘畅,王红艳. CD8+ T细胞活化与分化的分子机制[J]. 中国免疫学杂志,2017,33(4):481-487. [7] FERRARI C,BONI C,ROSSI M,et al. T cell regulation in HBV-related chronic liver disease[J]. J Hepatol,2017,66(5):1096-1098. [8] 孙建军,冯辉. CD8+T细胞耗竭及靶向CD8+ T细胞免疫治疗的研究进展[J]. 免疫学杂志,2016,32(9):816-820. [9] CHAIGNE-DELALANDE B,LI F Y,O'CONNOR G M,et al. Mg2+ regulates cytotoxic functions of NK and CD8 T cells in chronic EBV infection through NKG2D[J]. Science,2013,341(6142):186-191. [10] HUANG L R,WU H L,CHEN P J,et al. An immunocompetent mouse model for the tolerance of human chronic hepatitis B virus infection[J]. Proc Natl Acad Sci U S A,2006,103(47):17862-17867. [11] 董小岩,尉迟捷,王刚,等. 高嗜肝性8型重组腺相关病毒体内转导法制备乙型肝炎病毒持续感染小鼠模型[J]. 病毒学报,2010,26(6):425-431. [12] 石瑶,刘凤君,周仲辉,等. 恩替卡韦联合泼尼松对乙型肝炎病毒复制型小鼠体内病毒复制表达的影响[J]. 中华传染病杂志,2016,34(2):115-116. [13] 黄飞,胡勤明,贺新祥. 恩替卡韦抗乙型肝炎病毒应答不佳患者挽救方案的疗效比较[J]. 肝脏,2018,23(8):721-723. [14] PREDA C M,BAICUS C,NEGREANU L,et al. Effectiveness of entecavir treatment and predictive factors for virologic response[J]. Rev Esp Enferm Dig,2014,106(5):305-311. [15] 隋洪华,徐永红,刘涵云,等. 恩替卡韦治疗慢性乙型肝炎过程中应答不佳相关因素分析[J]. 胃肠病学和肝病学杂志,2014,23(3):323-328. [16] LI F Y,CHAIGNE-DELALANDE B,KANELLOPOULOU C,et al. Second messenger role for Mg2+ revealed by human T-cell immunodeficiency[J]. Nature,2011,475(7357):471-476. [17] 邵红玲,彭丽,彭晓明. 慢性HBV感染者外周血CD8+T细胞中Mg2+水平及其临床意义[J]. 内科,2017,12(6):731-734. [18] 唐宗生,郝友华,杨东亮.HBV持续性感染中T细胞功能耗竭的机制研究进展[J]. 中华肝脏病杂志,2012,20(11):871-873. [19] 杨洋,冷静,彭丽珊,等. 慢性HBV感染者CD8+ T细胞CD95、CD38、HLA-DR表达的变化和意义[J]. 广东医学,2016,37(20):3043-3045. [20] IM S J,HASHIMOTO M,GERNER M Y,et al. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy[J]. Nature, 2016, 537(7620):417-421. [21] BENGSCH B,MARTIN B,THIMME R. Restoration of HBV-specific CD8+ T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiation[J]. J Hepatol,2014,61(6):1212-1219. |